source
- FDA delays AstraZeneca breast cancer drug camizestrant PDUFA dateThe U.S. Food and Drug Administration has extended the PDUFA target date for AstraZeneca’s breast cancer candidate camizestrant, pushing the review timeline back by a few days. No new deadline was…
- Acceleron veterans and Westlake back new IPF biotech Oorja Bio with $30 million Series AEntrepreneurs who previously brought the drug Winrevair to market have launched a new biotech, Oorja Bio, to target idiopathic pulmonary fibrosis, a hard-to-treat lung disease. The company announc…